cow's milk protein allergy and enteropathy
Metabolic · 2015–2021
2decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides Treatment of cows' milk protein enteropathy, severe cows' milk protein enteropathy with failure to thrive, combined intolerance to cows' milk protein/soy… | Mar 2021 | Recommended with restriction | input received |
| amino acid synthetic formula Children aged 1 year and older with cow's milk protein enteropathy, severe cow's milk protein enteropathy with failure to thrive, combined intolerance to cow's… | Mar 2015 | Recommended with restriction | no section in document |
What the PBS pays
$24M in government benefit over 2024–25, across 47,780 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides | $23.9M |
| amino acid synthetic formula | $0.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.